



Tufts Center for the Study of Drug Development

TUFTS UNIVERSITY

Impact REPORT

ANALYSIS AND INSIGHT INTO CRITICAL DRUG DEVELOPMENT ISSUES

Drug approvals for neglected diseases increase along with more R&D funding

HIV/AIDS and malaria drugs accounted for 81% of approvals in 2000-09

- The annual rate of new product approvals for neglected diseases increased from an average of 1.8 in 1975-99 to 2.6 in 2000-09.
- Tufts CSDD found that 33 drugs targeting tropical diseases and tuberculosis had been approved worldwide in 1975-99, compared to 16 approvals reported in a landmark 2002 study.
- Between 1999 and 2008, annual funding for neglected diseases had risen 25-fold to \$2.5 billion.
- Vaccines have displaced drugs as the primary products being developed for neglected diseases.
- Public-private partnerships for new product development accounted for 46% of all approvals to treat neglected diseases in 2000-09, up from 15% in 1975-99.
- Government currently contributes 69% of all R&D funding for neglected disease drug development.